15-LOX Inhibitors: Biochemical Evaluation of Flurbiprofen and its Derivatives
15-LOX Inhibitors
Abstract
Objective: The synthesis, characterization, 15-LOX inhibition and molecular docking studies of a commercially available NSAID, flurbiprofen and its derivatives.
Study Design: Experimental study.
Place and Duration of Study: The study was carried out at Quaid-i-Azam University and Centre for Advanced Drug Research COMSATS University Islamabad, Abottabad Campus from March 2019 to February 2020.
Materials and Methods: The structural elucidation of the compounds (2-5) was carried out using infrared, 1H and 13C NMR spectroscopic studies. The structure of 4-amino-5-(1-(2-fluorobiphenyl-4-yl)-ethyl)-4H-1,2,4- triazole-3-thione (5) was also verified by single crystal X-ray diffraction (XRD) studies.
Results: The most potent inhibitor for 15-LOX (2) has an IC50value of0.18 ± 0.01 μM. Molecular docking results of 1, 2, 3 and cognate ligand inside the active site of 15-LOX (PDB ID: 1IK3) revealed significant correlation. Conclusion: This work represents cost-effective, reproducible and facile conversion of an aromatic monocarboxylic acid into potent derivatives.The molecules 2-(2-fluorobiphenyl-4-yl) propanoic acid (1) and its derivatives (2-5) possess 15-LOX inhibition and can be a prospective therapeutic target for chronic obstructive pulmonary disease.
References
Li QQ, Li Q, Jia JN, Liu ZQ, Zhou HH, Mao XY. Neurochem. Int. 2018; 118: 34-41.
Eleftheriadis N, Neochoritis CG, Leus NGJ, van der Wouden PE, Domling A, Dekker FJ. J. Med. Chem. 2015; 58: 7850-62.
van der Vlag R, Guo H, Hapko U, Eleftheriadis N, Monjas L, Dekker FJ, et al. Eur. J. Med. Chem. 2019; 174: 45-55.
Hu C, Ma S. Med. Chem. Comm. 2018; 9: 212-22.
Kuhn H, Banthiya S, Van Leyen K. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2015; 1851: 308-30.
Brash AR, Lipoxygenases J. Biol. Chem. 1999; 274: 23679–82.
Solomon EI, Zhou J, Neese F, Pavel EG. Chem. Biol. 1997; 4: 795−808.
Brash AR. J. Biol. Chem. 1999; 274: 23679−82.
Kuhn H, Thiele BJ. FEBS Lett. 1999; 449: 7–11.
Wang MT, Honn KV, Nie D. Cancer Metastasis Rev. 2007; 26: 525–34.
Kuhn H, Walther W, Kuban RJ. Prostaglandins Other Lipid Mediat. 2002; 68: 263-90.
Pooryaghoobi N, Bakavoli M, Alimardani M, Bazzazan T, Sadeghian H. Iran. J. Basic Med. Sci. 2013; 16: 784–9.
Setty B, Werner M, Hannun Y, Stuart M. Blood. 1992; 80: 2565-73.
Sultana C, Shen Y, Rattan V, Kalra K. J. Cell. Physiol. 1996;167: 477–87.
Abe M, Yoshimoto T, Zasshi NY. 2004; 124: 415–25.
Volovitz B, Welliver RC, De Castro G, Krystofik DA, Ogra PL. Pediatr. Res. 1988; 24: 504–7.
Gentile DL, Fireman, Skoner DP. Ann. Allergy. Asthma Immunol. 2003; 91: 270–4.
Funk CD. Nat. Rev. Drug Discov. 2005; 4: 664–72.
Klein M, Krainz K, Redwan IN, Dinér P, Grøtli M. Molecules. 2009; 14: 5124–43.
Bayrak H, Demirbas A, Demirbas N, Karaoglu SA. Eur. J. Med. Chem. 2009; 44: 4362–6.
El T, Ali S, Mohammed A, Kazak E. Eur. J. Chem. 2010; 1: 7–12.
Tehranchian S, Akbarzadeh T, Fazeli MR, Jamalifar H, Shafiee A. Bioorg. Med. Chem. Lett. 2005; 15: 1023–5.
Papadopoulou MV, Bloomer WD, Rosenzweig HS, Chatelain E, Kaiser M, Wilkinson SR, et al. J. Med. Chem. 2012; 55: 5554–65.
Küçükgüzel SG, Küçükgüzel I, Tatar E, Rollas S, Şahin F, Güllüce M, et al. J. Med. Chem. 2007; 42: 893–901.
Amir M, Kumar H, Javed SA, Bioorg. Med. Chem. Lett. 2007; 17: 4504–8.
Malterud KE, Rydland KM. J. Agric. Food Chem. 2000; 48: 5576-80.
Holmes RR, Schmid CG, Chandrasekhar V, Day R, Holmes JM. J. Am. Chem. Soc. 1987; 109: 1408–14.
Abbas S, Zaib S, Rahman S, Ali S, Hameed S, Tahir MN, et al. J. Iqbal, Med. Chem. 2019; 15: 298-310.
Sheldrick GM. SHELXS-97, Program for X-ray Crystal Structure Solution, Göttingen University, Göttingen, 1997. 30. Sheldrick GM. SHELXS-97, Program for X-ray Crystal Structure Refinement, Göttingen University, Göttingen,
Mustafa G, Khan IU, Ashraf M, Afzal I, Shahzad SA, Shafiq M. Bioorg. Med. Chem. 2012; 20: 2535–39.
Morris G, Huey R. J. Comput. Chem. 2009; 30: 2785–91.
Chemical Computing Group's Molecular Operating Environment (MOE) MOE 2019. 0201. http://www.chemcomp.com/MOEMolecular_Operating_ Environment.htm.
LeadIT version 2.3.2; BioSolveIT GmbH, Sankt Augustin, Germany, 2017, www.biosolveit.de/LeadIT.
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. J. Comput. Chem. 2004; 25: 1605–12.
BIOVIA Discovery Studio Client v19.1.0.18287. Accelrys Discovery Studio. Accelrys Software Inc, San Diego, 2019.
Shaojie Wu, Wenhui Zhang, Le Qi, Yinghui Ren, Haixia Ma. J Mol. Struc. 2019; 5: 171-82.
